Wearable Activity Tracking to Curb Hospitalizations

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of California, San Francisco

About this trial

This study is being done to collect patient generated health data to predict the risk of patients needing emergency department visits or hospitalization before, during. and after receiving radiation therapy.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age >= 18.

Eastern Cooperative Oncology Group (ECOG) performance status =< 2 or Karnofsky Performance Scale (KPS) >= 50%.

Able to understand study procedures and to comply with them for the entire length of the study.

Ability of individual or legal guardian/representative to understand a written informed consent document, and the willingness to sign it.

Disqualifiers

Participants bound to a wheelchair.

Participants unable to ambulate independently (needing assistance of cane or walker).

Trial population

Adult patients undergoing non-interventional, standard of care, radiotherapy (RT) at UCSF Department of Radiation Oncology

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Fitbit

    Device

    Participants will wear Fitbit device

  • Apple HealthKit-based devices

    Device

    Participants will wear personal device and share data with study team.

Treatment groups

260 Participants
are divided into 2 treatment groups
Group A: Observational Group I: Fitbit only1 intervention
Group B: Observational Group II: Fitbit + Apple HealthKit2 interventions

Trial outcomes

Primary outcomes

1

Area under the receiver operating characteristic curve (AUC-ROC) of the step count model

The AUC-ROC of the step count model will measure the performance of a classification model by plotting the rate of true positives against false positives, and the score ranges from 0 - 1. The higher the AUC, the better the model's performance at distinguishing between the positive and negative classes. The AUC-ROC will be reported including both estimates and confidence intervals. All models will be reported per up-to-date guidelines, such as Minimum Information about Clinical Artificial Intelligence Modeling (MI-CLAIM) and Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD). The performance metrics will only be calculated with respect to first acute care event.

Time frame
Up to 3 years
2

Calculation of a Brier Score

The Brier Score is a strictly proper score function or strictly proper scoring rule that measures the accuracy of probabilistic predictions. A Brier Score can take on any value between 0 and 1, with 0 being the best score achievable and 1 being the worst score achievable. The lower the Brier Score, the more accurate the prediction(s). The score will be reported including both estimates and confidence intervals. All models will be reported per up-to-date guidelines, such as MI-CLAIM and TRIPOD. The performance metrics will only be calculated with respect to first acute care event.

Time frame
Up to 3 years
3

Calculation of Log-Loss Score

Logarithmic loss indicates how close a prediction probability comes to the actual/corresponding true value. The Log-Loss Score can take on any value between 0 and 1. The more the predicted probability diverges from the actual value, the higher is the log-loss value. The log-loss value will be reported including both estimates and confidence intervals. All models will be reported per up-to-date guidelines, such as MI-CLAIM and TRIPOD. The performance metrics will only be calculated with respect to first acute care event.

Time frame
Up to 3 years
4

Area Under the Precision-Recall Curves (AUCPR)

The area under the precision-recall curve (AUCPR) is a single number summary of the information in the precision-recall (PR) curve. It represents the tradeoff between precision and recall for different thresholds, where high AUCPR indicates both high recall and high precision. The AUCPR will be reported including both estimates and confidence intervals. All models will be reported per up-to-date guidelines, such as MI-CLAIM and TRIPOD. The performance metrics will only be calculated with respect to first acute care event.

Time frame
Up to 3 years

Secondary outcomes

1

AUC-ROC for composite acute care

The AUC-ROC will be used to validate a previously developed model in the primary endpoint for predicting each ED visits or hospitalizations during external beam RT using continuous step counts before, during, and after treatment.

Time frame
Up to 3 years
2

Area under the receiver operating characteristic curve (AUC-ROC) for all cause acute care by group

The AUC-ROC will be used to validate the previously developed step-count model in the primary endpoint for predicting all-cause acute care for each of the two different device platforms.

Time frame
Up to 3 years
3

Mean squared error (MSE)

The MSE will be used to validate concordance of step counts across each of the device's platforms in the Apple group. Mean Squared Error (MSE) is a fundamental concept in statistics and machine learning in assessing the accuracy of the predictive models which measures the average squared difference between predicted values and the actual values in the dataset.

Time frame
Up to 3 years
4

Area under the receiver operating characteristic curve (AUC-ROC) for the composite acute care endpoint..

Validate the previously developed SHIELD-RT EHR-based model for predicting unplanned acute care (ED visit or hospitalization) to discover additional variables which may be predictors not previously included.

Time frame
Up to 3 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of California, San Francisco

Lead sponsor

National Cancer Institute (NCI)

Collaborator